Alessandro Vacca

Alessandro Vacca

Auto-generated profile, based on publicly available information

Alessandro Vacca

Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2018 in Neurology
Verified
Journal Article
Open access
PDF file
CTCristina Tassorelli
Cristina Tassorelli
LGLicia Grazzi
Licia Grazzi
MTMarina de Tommaso
Marina de Tommaso
GPGiulia Pierangeli
Giulia Pierangeli
PMPaolo Martelletti
Paolo Martelletti
DMDaniela Di Maro
Daniela Di Maro
Objective To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, double-blind, randomized, sham-controlled trial. Methods A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. Results nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%; p = 0.067; primary endpoint; logistic regression) after the first treated attack. A post hoc repeated-measures test provided further insight into the therapeutic benefit of nVNS through 30, 60, and 120 minutes (odds ratio 2.3; 95% confidence interval 1.2, 4.4; p = 0.012). nVNS demonstrated benefits across other endpoints including pain relief at 120 minutes and was safe and well-tolerated. Conclusion This randomized sham-controlled trial supports the abortive efficacy of nVNS as early as 30 minutes and up to 60 minutes after an attack. Findings also suggest effective pain relief, tolerability, and practicality of nVNS for the acute treatment of episodic migraine. ClinicalTrials.gov identifier NCT02686034. Classification of evidence This study provides Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 hours poststimulation (absolute difference 13.2%).

4 April 2018 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
IRInnocenzo Rainero
Innocenzo Rainero
FGFlora Govone
Flora Govone
AGAnnalisa Gai
Annalisa Gai
AVAlessandro Vacca
Alessandro Vacca
ERElisa Rubino
Elisa Rubino

20 May 2013 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
ERElisa Rubino
Elisa Rubino
AVAlessandro Vacca
Alessandro Vacca
FGFlora Govone
Flora Govone
PMPaola De Martino
Paola De Martino
LPLorenzo Pinessi
Lorenzo Pinessi
IRInnocenzo Rainero
Innocenzo Rainero

22 April 2018 in Cephalalgia
Verified
Journal Article
Closed access
ERElisa Rubino
Elisa Rubino
IRInnocenzo Rainero
Innocenzo Rainero
FGFrancesca Garino
Francesca Garino
CVCostanza Vicentini
Costanza Vicentini
FGFlora Govone
Flora Govone
PLPaolo Limone
Paolo Limone
Recent studies suggested a potential association between both overt and subclinical hypothyroidism and migraine. Aims of this study were to estimate the comorbidity of migraine in patients with subclinical hypothyroidism and to evaluate associated clinical characteristics. Using a case-control strategy, 151 consecutive subclinical hypothyroidism patients (mean age 48.36 ± 15.86 years) and 150 controls (mean age 50.86 ± 9.19 years) were recruited. In all subjects, migraine characteristics were collected through a direct interview. Clinical and biochemical parameters (thyroid-stimulating hormone, free triiodothyronine, free thyroxine, and anti-thyroid antibodies) were compared between subclinical hypothyroidism patients in comorbidity with migraine and subclinical hypothyroidism patients without migraine. The prevalence of lifetime migraine was significantly higher in subclinical hypothyroidism patients in comparison with controls (46% vs. 13%, p < 0.001; OR 5.80; 95% CI = 3.35–10.34). Both migraine without and with aura were significantly higher in subclinical hypothyroidism patients than controls (p < 0.001 and p = 0.010, respectively). Thyroid hormones and concentrations of antibodies did not differ between subclinical hypothyroidism patients with and without migraine. Interestingly, a comorbidity for autoimmune diseases was observed in subclinical hypothyroidism patients with migraine in respect to those without migraine (p = 0.005). Our data suggest that migraine is more frequent in patients with subclinical hypothyroidism in respect to controls. Further studies are needed in order to confirm this association.

1 January 2019 in Neurobiology of Aging
Verified
Journal Article
Closed access
ERElisa Rubino
Elisa Rubino
CMCecilia Mancini
Cecilia Mancini
SBSilvia Boschi
Silvia Boschi
PFPatrizia Ferrero
Patrizia Ferrero
MFMarina Ferrone
Marina Ferrone
IRInnocenzo Rainero
Innocenzo Rainero

17 December 2018 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Closed access
MZMilena Zucca
Milena Zucca
ERElisa Rubino
Elisa Rubino
AVAlessandro Vacca
Alessandro Vacca
FGFlora Govone
Flora Govone
AGAnnalisa Gai
Annalisa Gai
IRInnocenzo Rainero
Innocenzo Rainero
The purpose of the study was to determine the prevalence of suicidal ideation and attempts in patients with behavioral variant frontotemporal dementia (bvFTD), evaluating possible risk factors for suicidality. Risk of suicide was assessed using the Scale for Suicide Ideation (SSI) in 35 patients with bvFTD and 25 controls. According to SSI, 40% of patients with bvFTD had suicidal ideation in comparison to 8% of controls (P = .009). Four patients with bvFTD have attempted suicide versus none control (P = .006). Patients with bvFTD with suicide risk showed higher levels of anxiety, depression, stress, and hopelessness than patients without suicide risk (P < .001). Patients who attempted suicide were younger and had a longer disease duration than those with only suicide ideation. Intriguingly, 40% of patients with parkinsonism presented high level of suicide ideation. Our findings show that patients with bvFTD have a high risk of suicide. Additional studies in larger populations are needed to confirm our results.